Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:9256 |
Name | colorectal cancer |
Definition | A large intestine cancer that is located_in the colon and/or located_in the rectum. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer intestinal cancer large intestine cancer colorectal cancer |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00720785 | Phase I | Bortezomib | Natural Killer Cells and Bortezomib to Treat Cancer | Completed | USA | 0 |
NCT00730158 | Phase II | Irinotecan YIV-906 | A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT00940316 | Phase II | Irinotecan Erlotinib + Panitumumab | Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer | Completed | USA | 0 |
NCT00940381 | Phase I | Cetuximab + Sirolimus | Sirolimus and Cetuximab in Advanced Malignancies | Completed | USA | 0 |
NCT00996892 | Phase I | Cobimetinib + Pictilisib | Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors | Terminated | USA | 0 |
NCT01006369 | Phase II | Hydroxychloroquine Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01037790 | Phase II | Palbociclib | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | Completed | USA | 0 |
NCT01174121 | Phase II | Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer | Recruiting | USA | 0 |
NCT01218867 | Phase Ib/II | Anti-VEGFR2 CAR CD8 lymphocytes Cyclophosphamide Fludarabine Aldesleukin | Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes | Terminated | USA | 0 |
NCT01260415 | Phase II | Panitumumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Fluorouracil + Irinotecan + Leucovorin | A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases | Completed | CAN | 0 |
NCT01294826 | Phase I | Cetuximab + Luminespib | Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01312857 | Phase II | Panitumumab Fluorouracil + Irinotecan + Leucovorin Floxuridine | Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT01327612 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Ganitumab Bevacizumab Conatumumab | Open Label Extension Study of Conatumumab and AMG 479 | Completed | USA | ESP | 1 |
NCT01340300 | Phase II | Metformin | Exercise and Metformin in Colorectal and Breast Cancer Survivors | Completed | USA | 0 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT01358331 | Phase I | MK-8353 | A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001) | Terminated | 0 | |
NCT01436656 | Phase I | Encorafenib | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Completed | FRA | ESP | 3 |
NCT01543698 | Phase Ib/II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | CAN | BEL | 3 |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | FRA | ESP | CAN | BEL | 2 |
NCT01569984 | Phase II | Bevacizumab | Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis | Completed | CAN | 0 |
NCT01576666 | Phase Ib/II | Buparlisib + Sonidegib | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | Completed | USA | ITA | ESP | DEU | CAN | BEL | 2 |
NCT01587703 | Phase I | Molibresib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Completed | USA | FRA | ESP | 4 |
NCT01591421 | Phase Ib/II | Buparlisib + Panitumumab | P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer. | Completed | CAN | 0 |
NCT01607905 | Phase I | Selinexor | Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer | Completed | USA | CAN | 1 |
NCT01661972 | Phase Ib/II | Aflibercept + Capecitabine | Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01669720 | Phase II | Aflibercept | Adjuvant Aflibercept for Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01676714 | Phase II | Dovitinib | Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer | Completed | USA | 0 |
NCT01703390 | Phase II | Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Biomarker Directed Treatment in Metastatic Colorectal Cancer | Completed | AUT | 0 |
NCT01719380 | Phase Ib/II | Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 5 |
NCT01722162 | Phase II | Bevacizumab + Capecitabine | Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer | Completed | USA | 0 |
NCT01729923 | Phase II | Capecitabine Celecoxib | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01750918 | Phase II | Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | Completed | USA | ITA | FRA | ESP | BEL | 3 |
NCT01765582 | Phase II | Capecitabine + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01776307 | Phase II | Cetuximab + Napabucasin Capecitabine + Napabucasin Napabucasin + Panitumumab | A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer | Completed | USA | 0 |
NCT01792934 | Capecitabine + Oxaliplatin Bevacizumab + Capecitabine + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases (ORCHESTRA) | Recruiting | 2 | ||
NCT01871311 | Phase I | Cetuximab + Nilotinib | A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab | Terminated | USA | 0 |
NCT01874860 | Phase I | Doxycycline | Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients | Completed | USA | 0 |
NCT01876511 | Phase II | Pembrolizumab | Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | Completed | USA | 0 |
NCT01888965 | Phase II | Dovitinib | Maintenance Dovitinib for Colorectal and Pancreas Cancer | Terminated | USA | 0 |
NCT01923337 | Phase I | Alisertib + Irinotecan | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | Completed | USA | 0 |
NCT01927341 | Phase Ib/II | Binimetinib Panitumumab | Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | Completed | USA | ITA | FRA | ESP | CAN | BEL | 1 |
NCT01937715 | Phase II | Bevacizumab Gedatolisib Fluorouracil + Irinotecan + Leucovorin | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | Terminated | USA | ESP | CAN | 0 |
NCT01939223 | Phase III | Regorafenib | COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST) | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 7 |
NCT01952730 | Phase I | GVAX colorectal cancer vaccine | GVAX for Colorectal Cancer | Terminated | USA | 0 |
NCT01960023 | Phase Ib/II | Cetuximab + Neratinib | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT01966445 | Phase I | GSK2849330 | Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors | Completed | USA | 2 |
NCT01968109 | Phase I | Nivolumab + Relatlimab Relatlimab | Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | AUT | 8 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT01988896 | Phase I | Atezolizumab + Cobimetinib | A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors | Completed | USA | DEU | CAN | 3 |
NCT02004106 | Phase I | Cergutuzumab amunaleukin | A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | Completed | USA | FRA | ESP | 5 |
NCT02009449 | Phase I | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab Carboplatin Gemcitabine Docetaxel Pazopanib Capecitabine Paclitaxel Cisplatin Pegilodecakin Nab-paclitaxel | A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT02025803 | Phase I | Capecitabine + TAS-114 | A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02038699 | Phase Ib/II | ONC201 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | Withdrawn | USA | 0 |
NCT02041481 | Phase I | Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin | MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02060188 | Phase Ib/II | Nivolumab Ipilimumab | A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BEL | 2 |
NCT02083653 | Phase II | SYM004 Fluorouracil Capecitabine | Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer | Completed | USA | ITA | FRA | ESP | DEU | BEL | AUT | 3 |
NCT02110082 | Phase I | Cetuximab + Urelumab | Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer | Completed | USA | 0 |
NCT02122809 | Phase I | Chiauranib | Phase I Study of Chiauranib in Patients With Advanced Solid Tumors | Completed | 1 | |
NCT02124148 | Phase I | Cisplatin + Prexasertib Cetuximab + Prexasertib Pemetrexed Disodium + Prexasertib LY3023414 + Prexasertib Fluorouracil + Leucovorin + Prexasertib | A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer | Completed | USA | 0 |
NCT02141295 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin RO5520985 Bevacizumab + Fluorouracil + Leucovorin Fluorouracil + Leucovorin + RO5520985 Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab | A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE) | Terminated | USA | FRA | ESP | BEL | AUT | 2 |
NCT02162563 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin + Panitumumab Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases (CAIRO5) | Recruiting | BEL | 1 |
NCT02168777 | Phase Ib/II | Refametinib + Regorafenib Refametinib | Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer | Terminated | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT02187848 | Phase Ib/II | SAR408701 | Evaluation of SAR408701 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | FRA | ESP | CAN | 1 |
NCT02199223 | Phase I | Panitumumab + Regorafenib | Regorafenib + Panitumumab | Terminated | USA | 0 |
NCT02205398 | Phase Ib/II | Capmatinib + Cetuximab | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | Terminated | USA | ITA | FRA | ESP | DEU | CAN | BEL | 0 |
NCT02227667 | Phase II | Durvalumab | Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02260440 | Phase II | Azacitidine + Pembrolizumab | A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02268825 | Phase Ib/II | Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Pembrolizumab | Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers | Terminated | USA | 0 |
NCT02277093 | Phase II | Pacritinib | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | Terminated | USA | 0 |
NCT02278133 | Phase Ib/II | Cetuximab + Encorafenib + LGK974 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | Completed | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT02279433 | Phase I | Taletrectinib | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b | Completed | USA | 0 |
NCT02287025 | FDA approved | Regorafenib | A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes? | Terminated | USA | 0 |
NCT02298959 | Phase I | Aflibercept + Pembrolizumab | Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors | Active, not recruiting | USA | CAN | 0 |
NCT02310464 | Phase I | OBI-821 + OBI-833 | Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects | Completed | 1 | |
NCT02316340 | Phase II | Vorinostat Hydroxychloroquine Regorafenib | Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | Completed | USA | 0 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT02327078 | Phase Ib/II | Epacadostat + Nivolumab | A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers | Completed | USA | 1 |
NCT02335918 | Phase Ib/II | Nivolumab + Varlilumab | A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors | Completed | USA | 0 |
NCT02346955 | Phase I | CM-24 CM-24 + Pembrolizumab | Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | Terminated | USA | 1 |
NCT02365662 | Phase I | ABBV-221 | A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor | Terminated | USA | ESP | 0 |
NCT02399943 | Phase II | Panitumumab + Trametinib | A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer | Completed | CAN | 0 |
NCT02402036 | Phase II | Regorafenib | A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02425683 | Phase II | Regorafenib | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX | Terminated | USA | 0 |
NCT02432963 | Phase I | MVAp53 + Pembrolizumab | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | Active, not recruiting | USA | 0 |
NCT02433626 | Phase I | COTI-2 Cisplatin + COTI-2 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) | Unknown status | USA | 0 |
NCT02437071 | Phase II | Pembrolizumab | Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients | Active, not recruiting | USA | 0 |
NCT02444793 | Phase I | Mogamulizumab + Utomilumab | A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02448810 | Phase II | Fluorouracil + Leucovorin Imalumab Panitumumab | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02460198 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164) | Completed | 0 | |
NCT02460224 | Phase Ib/II | Ieramilimab Spartalizumab | Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 5 |
NCT02512172 | Phase I | Azacitidine + Pembrolizumab Pembrolizumab + Romidepsin Azacitidine + Pembrolizumab + Romidepsin | A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02516553 | Phase I | BI 894999 | BI 894999 First in Human Dose Finding Study in Advanced Malignancies | Completed | USA | FRA | ESP | DEU | BEL | 1 |
NCT02526017 | Phase I | Cabiralizumab Nivolumab | Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers | Completed | USA | 0 |
NCT02528357 | Phase I | GSK3174998 Pembrolizumab | GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors | Completed | USA | FRA | CAN | 1 |
NCT02538627 | Phase I | Seribantumab MM-151 | Phase 1 Combination Study of MM-151 and MM-121 | Terminated | USA | 0 |
NCT02540291 | Phase I | E7046 | Study of E7046 in Subjects With Selected Advanced Malignancies | Terminated | USA | FRA | 0 |
NCT02559024 | Phase I | MEDI6469 | Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02563002 | Phase III | Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab | Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) | Active, not recruiting | 0 | |
NCT02568046 | Phase Ib/II | Fluorouracil + Irinotecan + Leucovorin + SYM004 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | Terminated | USA | ESP | 0 |
NCT02568267 | Phase II | Entrectinib | Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 10 |
NCT02573220 | Phase I | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer | Withdrawn | ITA | 0 |
NCT02575781 | Phase I | SAR428926 | A Study of SAR428926 in Patients With Advanced Solid Tumors | Completed | FRA | ESP | 1 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 24 |
NCT02576665 | Phase I | Toca 511 + Toca FC | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6) | Terminated | USA | 0 |
NCT02599324 | Phase Ib/II | Cetuximab + Ibrutinib Ibrutinib + Paclitaxel Everolimus + Ibrutinib Docetaxel + Ibrutinib | A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | Completed | USA | ESP | 2 |
NCT02600949 | Phase I | Pembrolizumab | Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma | Recruiting | USA | 0 |
NCT02605044 | Phase III | Masitinib Fluorouracil + Irinotecan + Leucovorin | Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer | Terminated | FRA | 2 |
NCT02613650 | Phase I | Binimetinib + Fluorouracil + Irinotecan + Leucovorin | A Trial of mFOLFIRI With MEK162 in Patients With Advanced RAS (HRAS, NRAS, or KRAS) Positive Metastatic Colorectal Cancers | Active, not recruiting | USA | 0 |
NCT02630420 | Phase I | Cetuximab + Savolitinib | Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer | Withdrawn | 0 | |
NCT02632448 | Phase Ib/II | Gemcitabine + LY2880070 LY2880070 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | CAN | 0 |
NCT02636036 | Phase I | Enadenotucirev + Pembrolizumab | Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors | Completed | USA | 0 |
NCT02646748 | Phase I | Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab | Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | Completed | USA | 0 |
NCT02654639 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT02671955 | Phase I | JNJ-61610588 | A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer | Terminated | USA | 0 |
NCT02703571 | Phase Ib/II | Ribociclib + Trametinib | Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors | Terminated | USA | ESP | DEU | CAN | BEL | 2 |
NCT02713373 | Phase Ib/II | Cetuximab + Pembrolizumab | Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02713529 | Phase Ib/II | AMG 820 + Pembrolizumab | Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer | Completed | USA | ESP | DEU | CAN | BEL | 1 |
NCT02723955 | Phase I | GSK3359609 GSK3359609 + Pembrolizumab | Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 4 |
NCT02745769 | Phase I | Merestinib + Ramucirumab Abemaciclib + Ramucirumab | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | Completed | USA | FRA | 1 |
NCT02753127 | Phase III | Fluorouracil + Irinotecan + Leucovorin Napabucasin | A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 9 |
NCT02754856 | Phase I | Bevacizumab + Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab | Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases. | Completed | USA | 0 |
NCT02760797 | Phase I | Emactuzumab + Selicrelumab | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | Completed | USA | FRA | BEL | 0 |
NCT02785068 | Phase I | Fluorouracil + Irinotecan + Leucovorin + MM-151 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Withdrawn | 0 | |
NCT02811497 | Phase II | Azacitidine + Durvalumab | Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR) | Completed | CAN | 0 |
NCT02837263 | Phase I | Pembrolizumab | PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Completed | USA | FRA | 2 |
NCT02861300 | Phase Ib/II | Capecitabine + Telaglenastat | CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02870920 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies | Completed | CAN | 0 |
NCT02873195 | Phase II | Bevacizumab + Capecitabine Atezolizumab + Bevacizumab + Capecitabine | Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02888743 | Phase II | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer | Active, not recruiting | USA | CAN | 0 |
NCT02890069 | Phase I | LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab | A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | Completed | USA | ESP | DEU | 4 |
NCT02900664 | Phase I | Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab Canakinumab | A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) | Completed | USA | ITA | FRA | ESP | CAN | BEL | 3 |
NCT02906059 | Phase I | Adavosertib + Irinotecan | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT02928224 | Phase III | Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 19 |
NCT02934529 | Phase III | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Capecitabine + Fluorouracil + Leucovorin Regorafenib | Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab (AIO-KRK-0114) | Recruiting | DEU | 0 |
NCT02947165 | Phase I | NIS793 + Spartalizumab NIS793 | Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. | Completed | USA | ITA | DEU | CAN | AUT | 4 |
NCT02953782 | Phase Ib/II | Cetuximab + Hu5F9-G4 | Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02959437 | Phase Ib/II | Azacitidine + Epacadostat + Pembrolizumab | Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206) | Terminated | USA | ESP | 1 |
NCT02960594 | Phase I | INO-1400 + INO-9012 INO-1400 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse | Completed | USA | 0 |
NCT02961283 | Phase I | ASN003 | Study of ASN003 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02963831 | Phase Ib/II | Durvalumab + ONCOS-102 | A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies | Completed | USA | 0 |
NCT02965417 | Phase II | SYM004 | Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients | Withdrawn | 0 | |
NCT02981524 | Phase II | Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab | Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer | Completed | USA | 0 |
NCT02982694 | Phase II | Atezolizumab + Bevacizumab | Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer | Terminated | ITA | ESP | BEL | 1 |
NCT02983578 | Phase II | AZD9150 + Durvalumab | AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02991196 | Phase I | DS-8273a + Nivolumab | Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer | Terminated | USA | 0 |
NCT02992912 | Phase II | Atezolizumab | Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (SABR-PDL1) | Unknown status | FRA | 0 |
NCT03005002 | Phase I | Durvalumab + Tremelimumab | Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver | Completed | USA | 0 |
NCT03018405 | Phase Ib/II | NKR-2 cells | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) | Unknown status | USA | BEL | 0 |
NCT03031691 | Phase I | Brontictuzumab + Trifluridine | A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03035279 | Phase I | SC-006 | A Study of SC-006 in Subjects With Advanced Cancer | Terminated | USA | 0 |
NCT03050814 | Phase II | Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine Ad-CEA vaccine + Avelumab + Bevacizumab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 | Terminated | USA | 0 |
NCT03087591 | Phase I | APN401 | APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03096054 | Phase I | LY3143921 | A CR-UK Phase I Trial of LY3143921 | Active, not recruiting | 1 | |
NCT03099486 | Phase II | Fluorouracil + Leucovorin + Regorafenib | Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC | Terminated | USA | 0 |
NCT03101475 | Phase II | Durvalumab + Tremelimumab | Synergism of Immunomodulation and Tumor Ablation (ILOC) | Completed | FRA | DEU | AUT | 3 |
NCT03122509 | Phase II | Durvalumab + Tremelimumab | A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer | Completed | USA | 0 |
NCT03184870 | Phase Ib/II | BMS-813160 + Fluorouracil + Irinotecan + Leucovorin BMS-813160 + Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel BMS-813160 | A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors | Active, not recruiting | USA | ESP | DEU | CAN | BEL | 1 |
NCT03188965 | Phase I | BAY1895344 | First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas | Recruiting | USA | FRA | DEU | CAN | 5 |
NCT03189030 | Phase I | pLADD | Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT03203525 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Doxorubicin + Temsirolimus | Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer | Recruiting | USA | 0 |
NCT03206073 | Phase Ib/II | Durvalumab + Tremelimumab Durvalumab | A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | FRA | ESP | 7 |
NCT03215264 | Phase Ib/II | Entinostat + Hydroxychloroquine + Regorafenib | Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03223779 | Phase Ib/II | Trifluridine | Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | Recruiting | USA | 0 |
NCT03234712 | Phase I | ABBV-321 | A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands | Completed | USA | 2 |
NCT03239145 | Phase I | Pembrolizumab + Trebananib | Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor | Active, not recruiting | USA | 0 |
NCT03256344 | Phase I | Atezolizumab + Talimogene laherparepvec | Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases | Completed | USA | ESP | DEU | BEL | 2 |
NCT03259867 | Phase II | Nivolumab Pembrolizumab | Combination of TATE and PD-1 Inhibitor in Liver Cancer | Recruiting | USA | 0 |
NCT03263429 | Phase Ib/II | Irinotecan + Panitumumab + Telaglenastat | Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03265080 | Phase I | ADXS-NEO | Expressing Personalized Tumor Antigens Study | Terminated | USA | 0 |
NCT03271047 | Phase Ib/II | Binimetinib + Ipilimumab + Nivolumab Binimetinib + Nivolumab | Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation | Completed | USA | ESP | BEL | 2 |
NCT03289962 | Phase I | RO7198457 Atezolizumab + RO7198457 | A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors | Active, not recruiting | USA | ESP | DEU | CAN | BEL | 3 |
NCT03290937 | Phase I | Cetuximab + Irinotecan + Utomilumab | Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03307603 | Phase Ib/II | Nivolumab + Yttrium-90 microsphere therapy | Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer | Withdrawn | 0 | |
NCT03313778 | Phase I | mRNA-4157 + Pembrolizumab mRNA-4157 | Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) | Active, not recruiting | USA | 0 |
NCT03319459 | Phase I | FATE-NK100 FATE-NK100 + Trastuzumab Cetuximab + FATE-NK100 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03329950 | Phase I | CDX-1140 + CDX-301 CDX-1140 | A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03340558 | Phase II | Atezolizumab Atezolizumab + Cobimetinib | Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer (ATELIER) | Withdrawn | USA | 0 |
NCT03361228 | Phase Ib/II | Epacadostat + INCB001158 Epacadostat + INCB001158 + Pembrolizumab | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors | Terminated | USA | 0 |
NCT03363776 | Phase Ib/II | BMS-986277 BMS-986277 + Nivolumab | An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers | Terminated | USA | CAN | 0 |
NCT03374254 | Phase I | Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Binimetinib + Fluorouracil + Irinotecan + Leucovorin + Pembrolizumab | Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651) | Active, not recruiting | USA | CAN | 0 |
NCT03391232 | Phase I | PolyPEPI1018 | Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) | Completed | USA | ITA | 0 |
NCT03403634 | Phase I | Celecoxib + Interferon alpha-2b + Rintatolimod | Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver | Completed | USA | 0 |
NCT03407976 | Phase Ib/II | Pembrolizumab + Rivoceranib | Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies | Terminated | USA | 0 |
NCT03410927 | Phase Ib/II | TAS0728 | A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities | Terminated | USA | FRA | ESP | 1 |
NCT03414983 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (CheckMate 9X8) | Completed | USA | ESP | CAN | 2 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03422679 | Phase Ib/II | CB-103 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | Terminated | USA | FRA | ESP | DEU | 2 |
NCT03428126 | Phase II | Durvalumab + Trametinib | Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer | Completed | USA | 0 |
NCT03428958 | Phase I | A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment | Recruiting | USA | FRA | 1 | |
NCT03435640 | Phase Ib/II | NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 | A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies | Terminated | USA | 0 |
NCT03439462 | Phase Ib/II | Bevacizumab + Fluorouracil + Leucovorin + Nab-rapamycin + Oxaliplatin | ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03446157 | Phase II | Cetuximab + Palbociclib | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03454451 | Phase I | CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 | CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers | Active, not recruiting | USA | 1 |
NCT03457896 | Phase II | Cetuximab + Neratinib Neratinib + Trastuzumab | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | Active, not recruiting | USA | 0 |
NCT03473925 | Phase II | Navarixin + Pembrolizumab | Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034) | Completed | USA | CAN | 3 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03476681 | Phase I | NEO-201 | QUILT-3.017: Study of NEO-201 in Solid Tumors | Recruiting | USA | 0 |
NCT03485209 | Phase II | Tisotumab vedotin-tftv | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT03520946 | Phase III | Ramucirumab + Trifluridine-tipiracil hydrochloride Trifluridine-tipiracil hydrochloride | RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients (RAMTAS) | Active, not recruiting | DEU | 0 |
NCT03526835 | Phase I | MCLA-158 | A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Recruiting | USA | FRA | ESP | BEL | 1 |
NCT03530267 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Aflibercept + Fluorouracil + Leucovorin | Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer (ELDERLY) | Active, not recruiting | DEU | 0 |
NCT03531632 | Phase Ib/II | MGD007 + Retifanlimab | MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT03538028 | Phase I | INCAGN02385 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | Completed | USA | 0 |
NCT03547999 | Phase II | Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin CV301 + Fluorouracil + Leucovorin + Nivolumab + Oxaliplatin | A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC | Active, not recruiting | USA | 0 |
NCT03549338 | Phase II | Modotuximab Futuximab SYM004 | Sym004 Versus Futuximab or Modotuximab in Patients With mCRC | Terminated | USA | ITA | ESP | DEU | 0 |
NCT03555149 | Phase Ib/II | Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | Terminated | USA | FRA | 3 |
NCT03563157 | Phase Ib/II | Aldoxorubicin + ALT-803 + Avelumab + Capecitabine + Cetuximab + Cyclophosphamide + ETBX-011 + ETBX-021 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel + Oxaliplatin + Regorafenib + Trastuzumab Regorafenib | QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | Active, not recruiting | USA | 0 |
NCT03568539 | Phase Ib/II | Sintilimab | IBI308 in Subjects With Advanced/Metastatic Solid Malignancies | Completed | USA | 0 |
NCT03596372 | Phase I | BAY1834942 | Study of BAY1834942 in Patients With Solid Tumors | Completed | USA | CAN | 1 |
NCT03616574 | Phase I | CA102N CA102N + Trifluridine-tipiracil hydrochloride | First-in-human Study of CA102N Monotherapy and of CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors | Completed | USA | 0 |
NCT03628677 | Phase I | AB154 AB154 + Zimberelimab | A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies | Active, not recruiting | USA | 1 |
NCT03629756 | Phase I | Etrumadenant + Zimberelimab | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | Completed | USA | 1 |
NCT03631407 | Phase II | Pembrolizumab + Vicriviroc | Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046) | Completed | USA | CAN | 0 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | 1 |
NCT03656718 | Phase Ib/II | Nivolumab + rHuPH20 | A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) | Active, not recruiting | USA | ITA | FRA | ESP | 8 |
NCT03657641 | Phase Ib/II | Pembrolizumab + Regorafenib | Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03658772 | Phase I | Grapiprant + Pembrolizumab | Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03661632 | Phase Ib/II | BMS-986310 + Nivolumab | An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | BEL | 0 |
NCT03668431 | Phase II | Dabrafenib + Spartalizumab + Trametinib | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | Recruiting | USA | 0 |
NCT03693170 | Phase II | Binimetinib + Cetuximab + Encorafenib | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | AUT | 3 |
NCT03700294 | Phase I | ADCT-601 | Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors | Terminated | USA | 0 |
NCT03714958 | Phase I | Siremadlin + Trametinib | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) | Recruiting | FRA | 0 |
NCT03720678 | Phase I | Etrumadenant + Fluorouracil + Leucovorin + Oxaliplatin | A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Gastrointestinal (GI) Malignancies | Completed | USA | 1 |
NCT03724071 | Phase Ib/II | Flucytosine + TG6002 | Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors. | Recruiting | FRA | ESP | BEL | 0 |
NCT03735628 | Phase Ib/II | Copanlisib + Nivolumab | An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | CAN | 0 |
NCT03761914 | Phase Ib/II | Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | Active, not recruiting | USA | 0 |
NCT03775850 | Phase Ib/II | EDP1503 EDP1503 + Pembrolizumab | A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors | Completed | USA | CAN | 0 |
NCT03785210 | Phase II | Nivolumab + Tadalafil + Vancomycin | Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers | Completed | USA | 0 |
NCT03791398 | Phase Ib/II | Nivolumab + ONC201 | BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC (379) | Terminated | USA | 0 |
NCT03792724 | Phase Ib/II | Nivolumab + Urelumab | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors (INTRUST) | Unknown status | ESP | 0 |
NCT03795311 | Phase Ib/II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) | Unknown status | FRA | 0 |
NCT03796884 | Phase II | Linaclotide | Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03797326 | Phase II | Lenvatinib + Pembrolizumab | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 11 |
NCT03798626 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + XOMA 052 Paclitaxel + Ramucirumab + XOMA 052 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + XOMA 052 Cabozantinib + XOMA 052 | Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers | Active, not recruiting | USA | ITA | ESP | DEU | CAN | BEL | 9 |
NCT03802747 | Phase I | Durvalumab + Tremelimumab Durvalumab | Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver Metastases | Withdrawn | 0 | |
NCT03819387 | Phase I | NBF-006 | A Study of NBF-006 in Non-Small Cell Lung, Pancreatic, or Colorectal Cancer | Recruiting | USA | 0 |
NCT03829462 | Phase III | Regorafenib Irinotecan + Regorafenib | Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients (NEXT-REGIRI) | Recruiting | FRA | 0 |
NCT03844620 | Phase II | Regorafenib Trifluridine-tipiracil hydrochloride Regorafenib + Trifluridine-tipiracil hydrochloride | Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT03844750 | Phase II | Fluorouracil + Leucovorin + Oxaliplatin Pembrolizumab | Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery | Recruiting | USA | 0 |
NCT03851614 | Phase II | Cediranib + Durvalumab Durvalumab + Olaparib | Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER) | Active, not recruiting | CAN | 0 |
NCT03865082 | Phase II | IMO-2125 + Ipilimumab + Nivolumab | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Active, not recruiting | USA | 0 |
NCT03871959 | Phase I | Pembrolizumab + Xevinapant | Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma (CATRIPCA) | Completed | FRA | 0 |
NCT03875313 | Phase Ib/II | Talazoparib + Telaglenastat | Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors | Terminated | USA | 0 |
NCT03875820 | Phase I | Defactinib + RO5126766 | Phase I Trial of VS-6063 and RO5126766. (FRAME) | Recruiting | 1 | |
NCT03879811 | Phase II | Nivolumab Temozolomide | Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer | Withdrawn | 0 | |
NCT03891953 | Phase I | DKY709 DKY709 + Spartalizumab | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | Active, not recruiting | USA | ESP | DEU | 3 |
NCT03900442 | Phase I | GGTI-2418 | Phase 1 Study of PTX-100 in Patients With Advanced Malignancies | Recruiting | 1 | |
NCT03929666 | Phase II | Cisplatin + Gemcitabine Cisplatin + Fluorouracil + ZW25 Capecitabine + Oxaliplatin + ZW25 Fluorouracil + Leucovorin + Oxaliplatin + ZW25 Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + ZW25 | A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer | Recruiting | USA | CAN | 2 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | 2 |
NCT03947385 | Phase Ib/II | IDE196 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Recruiting | USA | CAN | 1 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Active, not recruiting | USA | 0 |
NCT03965845 | Phase Ib/II | Palbociclib + Telaglenastat | A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors | Completed | USA | 0 |
NCT03970382 | Phase I | NeoTCR-P1 T-cells + Nivolumab NeoTCR-P1 T-cells | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | Suspended | USA | 0 |
NCT03981614 | Phase II | Trifluridine-tipiracil hydrochloride Binimetinib + Palbociclib | Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03983993 | Phase II | Niraparib + Panitumumab | Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect) | Active, not recruiting | USA | 0 |
NCT03990233 | Phase I | Effi-DEM Effi-DEM + Ezabenlimab | A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours | Recruiting | FRA | BEL | 0 |
NCT04000529 | Phase I | Spartalizumab + TNO155 Ribociclib + TNO155 | Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies | Active, not recruiting | USA | ESP | DEU | BEL | 5 |
NCT04008030 | Phase III | Nivolumab Fluorouracil + Irinotecan + Leucovorin Cetuximab Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab Ipilimumab + Nivolumab | A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 16 |
NCT04008797 | Phase I | Lenvatinib E7386 + Lenvatinib | A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor | Recruiting | USA | 3 |
NCT04034459 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) | Active, not recruiting | DEU | 0 |
NCT04041310 | Phase I | GAd-209-FSP + MVA-209-FSP | Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | Recruiting | USA | ESP | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Terminated | USA | ITA | FRA | ESP | 1 |
NCT04046445 | Phase Ib/II | ATP128 + Ezabenlimab ATP128 ATP128 + Ezabenlimab + VSV-GP128 | Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01) | Recruiting | USA | BEL | 1 |
NCT04060342 | Phase Ib/II | GB1275 GB1275 + Pembrolizumab GB1275 + Gemcitabine + Nab-paclitaxel | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | Terminated | USA | 1 |
NCT04068896 | Phase I | NGM120 | Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy | Active, not recruiting | USA | 0 |
NCT04069026 | Phase I | BAY2416964 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | Recruiting | USA | ESP | DEU | CAN | 2 |
NCT04072198 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR) | Unknown status | ITA | 0 |
NCT04073615 | Phase Ib/II | Rivoceranib + Trifluridine-tipiracil hydrochloride Rivoceranib Trifluridine-tipiracil hydrochloride | Phase 1b/2 Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04083599 | Phase Ib/II | GEN1042 | GEN1042 Safety Trial in Subjects With Malignant Solid Tumors | Recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT04096417 | Phase II | Pemigatinib | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | Active, not recruiting | USA | 0 |
NCT04108481 | Phase Ib/II | Durvalumab | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer (iRE-C) | Suspended | USA | 0 |
NCT04117087 | Phase I | Ipilimumab + Nivolumab + Poly ICLC | Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer | Recruiting | USA | 0 |
NCT04117958 | Phase I | AMG 199 | Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers | Active, not recruiting | USA | FRA | ESP | DEU | AUT | 4 |
NCT04134312 | Phase I | MVA-BN-Brachyury | A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer | Completed | USA | 0 |
NCT04140526 | Phase Ib/II | ONC-392 ONC-392 + Pembrolizumab | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Recruiting | USA | 1 |
NCT04145193 | Phase II | Durvalumab + Fluorouracil + Leucovorin + Oleclumab + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin Durvalumab + Fluorouracil + Leucovorin + Monalizumab + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin | Novel Oncology Therapies in Combination With Adjuvant Chemo in High-risk MSS-CRC | Withdrawn | 0 | |
NCT04164069 | Phase I | Bevacizumab + Dasatinib + Fluorouracil + Leucovorin + Oxaliplatin | Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab | Recruiting | USA | 0 |
NCT04166383 | Phase II | Nivolumab + VB-111 | VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC) | Completed | USA | 0 |
NCT04172597 | Phase II | Poziotinib | A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies | Terminated | USA | 0 |
NCT04189055 | Phase II | Cetuximab + Irinotecan Cetuximab | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) | Recruiting | FRA | 0 |
NCT04194034 | Phase Ib/II | Flucytosine + TG6002 | Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal Cancer | Recruiting | FRA | 1 |
NCT04244552 | Phase I | ATRC-101 | First-in-Human Dose Escalation Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT04246671 | Phase Ib/II | TAEK-VAC-HerBy TAEK-VAC-HerBy + unspecified ERBB2 antibody + unspecified immune checkpoint inhibitor Pertuzumab + TAEK-VAC-HerBy + Trastuzumab Ado-trastuzumab emtansine + TAEK-VAC-HerBy TAEK-VAC-HerBy + Trastuzumab | Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients | Recruiting | USA | 0 |
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | 1 |
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04259450 | Phase Ib/II | AFM24 | Study to Assess AFM24 in Advanced Solid Cancers | Recruiting | USA | ESP | DEU | 2 |
NCT04270864 | Phase I | IMO-2125 + Ipilimumab + Nivolumab | Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers (PRIMO) | Active, not recruiting | FRA | 0 |
NCT04301011 | Phase Ib/II | TBio-6517 Pembrolizumab + TBio-6517 | Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors (RAPTOR) | Active, not recruiting | USA | CAN | 1 |
NCT04330664 | Phase Ib/II | Adagrasib + TNO155 | Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2) | Active, not recruiting | USA | 0 |
NCT04332653 | Phase Ib/II | NT-I7 + Pembrolizumab | NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (KEYNOTE A60) | Recruiting | USA | 0 |
NCT04336241 | Phase I | Nivolumab + RP2 RP2 | Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors | Recruiting | ESP | 1 |
NCT04338685 | Phase I | RO7119929 + Tocilizumab | A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases | Completed | USA | ESP | 4 |
NCT04344795 | Phase I | TPST-1495 Pembrolizumab + TPST-1495 | Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT04381650 | Phase Ib/II | Pembrolizumab + Subasumstat | A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors | Recruiting | USA | 9 |
NCT04421820 | Phase I | BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin | BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Recruiting | USA | CAN | 1 |
NCT04425239 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE) | Completed | ITA | 0 |
NCT04429542 | Phase I | BCA101 BCA101 + Pembrolizumab | Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors | Recruiting | USA | CAN | 0 |
NCT04430738 | Phase Ib/II | Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib | Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Recruiting | USA | 1 |
NCT04432857 | Phase I | E7046 + Pembrolizumab | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Recruiting | USA | FRA | 0 |
NCT04449874 | Phase I | Atezolizumab + GDC-6036 Bevacizumab + GDC-6036 Cetuximab + GDC-6036 Erlotinib + GDC-6036 GDC-6036 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation | Recruiting | USA | ITA | ESP | CAN | BEL | 13 |
NCT04450836 | Phase II | Regorafenib + Trifluridine-tipiracil hydrochloride | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) | Recruiting | FRA | BEL | 0 |
NCT04468607 | Phase I | BLYG8824A | A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer | Recruiting | USA | ESP | 1 |
NCT04488003 | Phase II | Ulixertinib | Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | Active, not recruiting | USA | 0 |
NCT04505839 | Phase I | STP1002 | First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors | Recruiting | USA | 0 |
NCT04508140 | Phase II | BO-112 + Pembrolizumab | Study of BO-112 With Pembrolizumab for Colorectal or Gastric/GEJ Cancer With Liver Metastasis | Terminated | ITA | ESP | BEL | 0 |
NCT04511039 | Phase I | Talazoparib + Trifluridine-tipiracil hydrochloride | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | Recruiting | USA | 0 |
NCT04513951 | Phase II | Avelumab + Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients (AVETRIC) | Active, not recruiting | ITA | 0 |
NCT04515394 | Phase II | Cetuximab + Tepotinib | Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | Terminated | USA | ITA | FRA | ESP | BEL | 3 |
NCT04534218 | Phase II | Aspirin + Capecitabine + Cyclophosphamide + Regorafenib | Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer (REPROGRAM-01) | Active, not recruiting | FRA | 0 |
NCT04535401 | Phase I | BAY1895344 + Fluorouracil + Irinotecan + Leucovorin | Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines | Recruiting | USA | 0 |
NCT04564898 | Phase Ib/II | Bevacizumab + Capecitabine + Trifluridine-tipiracil hydrochloride | Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients. (TriComB) | Recruiting | ITA | 0 |
NCT04585035 | Phase Ib/II | D-1553 | Study to Evaluate D-1553 in Subjects With Solid Tumors | Recruiting | USA | 3 |
NCT04587128 | Phase II | Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | Recruiting | USA | 0 |
NCT04592653 | Phase II | ALKS 4230 + Pembrolizumab | A Study of ALKS 4230 on the Tumor Microenvironment (ARTISTRY-3) | Recruiting | USA | 0 |
NCT04595266 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin + unspecified EGFR antibody Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + unspecified EGFR antibody | Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL) | Recruiting | ESP | 0 |
NCT04602117 | Phase I | Paclitaxel + Trastuzumab Duocarmazine | Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | Withdrawn | USA | 0 |
NCT04606381 | Phase I | Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 | A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA) | Recruiting | USA | CAN | 2 |
NCT04607421 | Phase III | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | 23 |
NCT04609579 | Phase I | SNX281 Pembrolizumab + SNX281 | Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | 0 |
NCT04616196 | Phase Ib/II | Cetuximab + NKTR-255 | A Phase 1b/2 Study of NKTR 255 in Combination With Cetuximab in Solid Tumors | Completed | USA | 0 |
NCT04622774 | Phase I | IMGC936 | First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors | Recruiting | USA | ITA | ESP | 0 |
NCT04645797 | Phase I | APR003 | A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions | Completed | USA | 0 |
NCT04659382 | Phase II | Atezolizumab + Bevacizumab + Capecitabine + Oxaliplatin | Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI) | Recruiting | FRA | 0 |
NCT04665921 | Phase I | SGN-STNV | A Study of SGN-STNV in Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | CAN | 1 |
NCT04683939 | Phase Ib/II | BNT141 BNT141 + Gemcitabine + Nab-paclitaxel | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Active, not recruiting | USA | ESP | CAN | 0 |
NCT04701476 | Phase II | Pembrolizumab + Tirapazamine | TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Recruiting | USA | 1 |
NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
NCT04705818 | Phase II | Durvalumab + Tazemetostat | Combining Epigenetic And Immune Therapy to Beat Cancer. (CAIRE) | Recruiting | FRA | 0 |
NCT04708470 | Phase Ib/II | Bintrafusp alfa + Entinostat + NHS-IL12 Entinostat + NHS-IL12 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | Recruiting | USA | 0 |
NCT04713891 | Phase I | KF-0210 Atezolizumab + KF-0210 | A Study of KF-0210 in Advanced Solid Tumors Patients | Recruiting | 1 | |
NCT04714983 | Phase I | DNX-2440 | DNX-2440 for Resectable Colorectal Liver Metastasis | Recruiting | USA | 0 |
NCT04717375 | Phase Ib/II | BND-22 | Study of BND-22 in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04761614 | Phase I | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin + Riluzole | Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT04776655 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) | Recruiting | ITA | 0 |
NCT04787341 | Phase II | Regorafenib Panitumumab | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) | Recruiting | ITA | 0 |
NCT04795661 | Phase II | Pembrolizumab | Immunotherapy in MSI/dMMR Tumors in Perioperative Setting. (IMHOTEP) | Recruiting | FRA | 0 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04808362 | Phase Ib/II | OMO-103 | Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours (MYCure) | Active, not recruiting | ESP | 0 |
NCT04836195 | Phase I | PCLX-001 | Phase I Trial of PCLX-001 in B-cell Non-Hodgkin Lymphoma and Advanced Solid Malignancies | Recruiting | CAN | 0 |
NCT04837196 | Phase Ib/II | ASP7517 + Pembrolizumab ASP7517 | Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen | Active, not recruiting | USA | 0 |
NCT04844073 | Phase Ib/II | MVC-101 | A Dose Escalation and Expansion Study of MVC-101 in Patients With Advanced Cancer | Recruiting | 1 | |
NCT04854434 | Phase II | Trifluridine-tipiracil hydrochloride Pembrolizumab + Selinexor Selinexor | A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations | Terminated | USA | 0 |
NCT04870034 | Phase I | Binimetinib + Palbociclib | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | Recruiting | USA | 0 |
NCT04874207 | FDA approved | Regorafenib | Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients With Metastatic Colorectal Cancer Treated With REgorafenib (RePERSO) | Recruiting | FRA | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT04895722 | Phase II | MK-4280A MK-7684A MK-1308A MK-4830 + Pembrolizumab Pembrolizumab | Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 10 |
NCT04903873 | Phase Ib/II | EU101 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT04907539 | Phase II | Denosumab + Nivolumab + RXC004 Denosumab + RXC004 | A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC) | Recruiting | USA | ESP | 2 |
NCT04914286 | Phase Ib/II | GFH018 + Toripalimab | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | Recruiting | 1 | |
NCT04943900 | Phase I | BMS-986416 + Nivolumab BMS-986416 | A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | Recruiting | USA | CAN | BEL | 4 |
NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) | Recruiting | USA | ITA | ESP | BEL | 2 |
NCT04969835 | Phase I | AVA6000 | A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours | Recruiting | USA | 1 |
NCT04973163 | Phase I | BI 1823911 + Midazolam BI 1701963 + BI 1823911 | A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation | Recruiting | USA | ESP | BEL | 1 |
NCT04976634 | Phase II | Belzutifan + Lenvatinib + Pembrolizumab | Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | Recruiting | USA | FRA | ESP | BEL | 6 |
NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Recruiting | USA | ESP | BEL | AUT | 2 |
NCT04991740 | Phase I | JNJ-78306358 | A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Completed | ESP | 1 |
NCT05001282 | Phase Ib/II | ELU001 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) | Recruiting | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
NCT05007132 | Phase II | Bevacizumab + Trifluridine-tipiracil hydrochloride Panitumumab + Trifluridine-tipiracil hydrochloride | Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer | Recruiting | DEU | 0 |
NCT05039177 | Phase Ib/II | Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) | Recruiting | USA | 0 |
NCT05041972 | Phase II | ARX-788 | ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02) | Withdrawn | USA | 0 |
NCT05047536 | Phase I | KZR-261 | KZR-261 in Subjects With Advanced Solid Malignancies | Recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | 1 | |
NCT05061017 | Phase II | Cyclophosphamide + Nivolumab + PG545 Nivolumab + PG545 | Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC) | Recruiting | USA | 0 |
NCT05061537 | Phase I | PF-06801591 + PF-07263689 PF-07263689 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Terminated | USA | 0 |
NCT05062317 | Phase II | Capecitabine Leucovorin Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Risk-Stratified Adjuvant Therapy: ctDNA-Directed Post-Hepatectomy Chemotherapy for Patients With Resectable Colorectal Liver Metastases | Recruiting | USA | 0 |
NCT05067283 | Phase I | MK-1084 MK-1084 + Pembrolizumab Carboplatin + MK-1084 + Pembrolizumab + Pemetrexed Disodium Cetuximab + MK-1084 Cetuximab + Fluorouracil + Leucovorin + MK-1084 + Oxaliplatin | A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Advanced Solid Tumors (MK-1084-001) | Recruiting | USA | ESP | CAN | 11 |
NCT05069935 | Phase I | Atezolizumab + FT538 Cetuximab + FT538 FT538 + Trastuzumab FT538 + Pembrolizumab FT538 + Nivolumab Avelumab + FT538 Cyclophosphamide + Fludarabine | FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT05076552 | Phase I | TACH101 | A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer | Recruiting | USA | 0 |
NCT05084859 | Phase I | Abiraterone + Prednisone + SM08502 Fluorouracil + Irinotecan + Leucovorin + Panitumumab + SM08502 Docetaxel + SM08502 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | 1 |
NCT05091346 | Phase Ib/II | E7386 + Pembrolizumab | A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | Recruiting | USA | ESP | 2 |
NCT05091528 | Phase Ib/II | SBT6050 + Trastuzumab deruxtecan SBT6050 + Trastuzumab + Tucatinib Capecitabine + SBT6050 + Trastuzumab + Tucatinib | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | Terminated | USA | 0 |
NCT05098405 | Phase I | MP0317 | First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors | Recruiting | FRA | 1 |
NCT05099549 | Phase Ib/II | AFM24 + SNK01 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | Recruiting | USA | 0 |
NCT05104567 | Phase II | Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 5 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | 1 |
NCT05116891 | Phase Ib/II | Cisplatin + Gemcitabine + Nidanilimab Docetaxel + Nidanilimab Fluorouracil + Leucovorin + Nidanilimab + Oxaliplatin | A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors | Active, not recruiting | FRA | ESP | 0 |
NCT05118841 | Phase I | ZX-4081 | Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05121948 | Phase I | HC-7366 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | Recruiting | USA | 0 |
NCT05141721 | Phase II | Atezolizumab + GRT-C901 + GRT-R902 + Ipilimumab | A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT05167409 | Phase II | Cetuximab + Evorpacept + Pembrolizumab | A Study of ALX148 With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT05176665 | Phase Ib/II | EMB-01 | EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers | Recruiting | USA | 1 |
NCT05185947 | Phase II | Nilotinib + Paclitaxel | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Ovarian, Colorectal, or Appendiceal Cancer | Recruiting | USA | 0 |
NCT05201612 | Phase II | Olaparib + Pembrolizumab | Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). (PEMBROLA) | Recruiting | ESP | 0 |
NCT05203172 | FDA approved | Encorafenib Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib Binimetinib + Cetuximab + Encorafenib Binimetinib | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | Recruiting | USA | ITA | FRA | ESP | CAN | 7 |
NCT05238558 | Phase I | FMPV-1 + Sargramostim | Safety and Immune Response to FMPV-1 | Active, not recruiting | 1 | |
NCT05243862 | Phase II | Atezolizumab + PolyPEPI1018 | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer. | Recruiting | USA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | BEL | 2 |
NCT05259696 | Phase Ib/II | E-602 E-602 + Pembrolizumab | Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) (GLIMMER-01) | Recruiting | USA | 0 |
NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 | |
NCT05277051 | Phase I | GSK4381562 Dostarlimab-gxly + EOS-448 + GSK4381562 Dostarlimab-gxly + GSK4381562 | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors | Recruiting | USA | CAN | 1 |
NCT05307874 | Phase Ib/II | Aldesleukin + ICT01 | Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (EVICTION-2) | Recruiting | FRA | 0 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC) | Recruiting | USA | 2 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Recruiting | USA | 0 |
NCT05350501 | Phase II | EO2040 + Nivolumab | EO2040 in Combination With Nivolumab, for Treatment of Patients With Minimal Residual Disease of Colorectal Cancer (CLAUDE) | Recruiting | USA | 0 |
NCT05358249 | Phase Ib/II | JDQ443 + Ribociclib JDQ443 + Trametinib Cetuximab + JDQ443 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (KontRASt-03) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | 2 |
NCT05358379 | Phase Ib/II | CYC140 | A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Recruiting | USA | ESP | 1 |
NCT05394103 | Phase Ib/II | Q901 | Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05397171 | Phase Ib/II | AZD8853 | A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours | Recruiting | USA | FRA | ESP | CAN | 1 |
NCT05411133 | Phase I | ARB202 + Atezolizumab ARB202 | Treatment of ARB202 Advanced Gastrointestinal Cancer Patients | Recruiting | 3 | |
NCT05427487 | Phase I | IVX037 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | Recruiting | 1 | |
NCT05446129 | Phase I | Effi-DEM + Pembrolizumab Effi-DEM + Ezabenlimab | A Study in People With Colorectal Cancer to Test Whether Ezabenlimab or Pembrolizumab in Combination With BI 765063 Lead to Side Effects or Delays in Surgery | Recruiting | USA | 0 |
NCT05453825 | Phase II | Irinotecan + Navicixizumab Navicixizumab Navicixizumab + Paclitaxel | A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05462236 | Phase II | ETC-1907206 ETC-1907206 + Irinotecan ETC-1907206 + Pembrolizumab | MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer | Recruiting | 1 | |
NCT05462613 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Leucovorin + Oxaliplatin + Regorafenib Aspirin + Bevacizumab + Capecitabine + Cyclophosphamide + Fluorouracil + Irinotecan + Leucovorin + Regorafenib Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin | Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (REPROGRAM-02) | Recruiting | FRA | 0 |
NCT05464030 | Phase I | M9140 | Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors | Recruiting | USA | ESP | 1 |
NCT05480306 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin DKN-01 + Fluorouracil + Irinotecan + Leucovorin Fluorouracil + Irinotecan + Leucovorin | Phase 2 Study of DKN-01 in Colorectal Cancer (DeFianCe) | Recruiting | USA | DEU | 1 |
NCT05496595 | Phase I | DCBY02 | DCBY02 or DCSZ11 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Recruiting | USA | 0 |
NCT05513742 | Phase II | CTX-009 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT05518032 | Phase II | Pembrolizumab | Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) | Not yet recruiting | USA | 0 |
NCT05533697 | Phase Ib/II | mRNA-4359 + Pembrolizumab mRNA-4359 | Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Recruiting | USA | 1 |
NCT05544929 | Phase I | KFA115 + Tislelizumab KFA115 | A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination With Tislelizumab in Patients With Select Advanced Cancers | Recruiting | CAN | 3 |
NCT05547321 | Phase I | OMTX705 + Pembrolizumab OMTX705 | Efficacy and Safety Study of OMTX705, Monotherapy and Pembrolizumab-combined, in Subjects With Advanced Solid Tumors. | Recruiting | USA | ESP | 0 |
NCT05565417 | Phase Ib/II | IMT-009 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | Recruiting | USA | 0 |
NCT05571839 | Phase I | SGN-BB228 | A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors | Recruiting | USA | 0 |
NCT05572684 | Phase Ib/II | NC410 + Pembrolizumab | A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05573035 | Phase I | LYL845 | A Study to Investigate LYL845 in Adults With Solid Tumors | Recruiting | USA | 0 |
NCT05576896 | Phase II | Encorafenib + Hydroxychloroquine + Panitumumab Cetuximab + Encorafenib + Hydroxychloroquine | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | Recruiting | USA | 0 |
NCT05578092 | Phase Ib/II | Adagrasib + MRTX0902 MRTX0902 | A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway | Recruiting | USA | 0 |
NCT05584709 | Phase I | STI-6129 | Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors | Not yet recruiting | USA | 0 |
NCT05585034 | Phase I | Pembrolizumab + XmAb808 | Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb808 in Combination With Pembrolizumab in Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05585320 | Phase Ib/II | IMM-1-104 | A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | 0 |
NCT05593328 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Onvansertib Bevacizumab + Fluorouracil + Irinotecan + Leucovorin | Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | Recruiting | USA | 0 |
NCT05597839 | Phase Ib/II | DF9001 DF9001 + Nivolumab | Study of DF9001 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05607498 | Phase I | EMB-07 | First in Human Study of EMB-07 in Locally Advanced/Metastatic Solid Tumors | Recruiting | 2 | |
NCT05631574 | Phase I | BMF-219 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer | Recruiting | USA | 0 |
NCT05636215 | Phase Ib/II | Orismilast | A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | Not yet recruiting | 1 | |
NCT05646797 | Phase I | ASP2074 | A Study of ASP2074 in Adults With Solid Tumors | Recruiting | USA | 1 |
NCT05650203 | Phase I | JS006 + JS009 + Toripalimab JS009 | A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies | Withdrawn | 0 | |
NCT05652855 | Phase Ib/II | MHB088C | Study of MHB088C in Participants With Advanced or Metastatic Solid Tumors | Not yet recruiting | 1 | |
NCT05668585 | Phase Ib/II | CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors | Recruiting | USA | FRA | ESP | 0 |
NCT05683418 | Phase I | TOS-358 | A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors | Recruiting | USA | 0 |
NCT05684965 | Phase I | XTX301 | XTX301 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05694936 | Phase II | Cetuximab + Panitumumab Cetuximab + Panitumumab + Valproic acid | Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer | Recruiting | 1 | |
NCT05718557 | Phase I | PYX-106 | Study of PYX-106 in Solid Tumors | Recruiting | USA | 0 |
NCT05719558 | Phase I | ASP1002 | A Study of ASP1002 in Adults for Treatment of Solid Tumors | Recruiting | USA | 0 |
NCT05731271 | Phase Ib/II | TST003 | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | Recruiting | USA | 0 |
NCT05731947 | Phase Ib/II | Revumenib | Evaluation of SNDX-5613 in Participants With Colorectal Cancer and Other Solid Tumors | Recruiting | USA | 0 |
NCT05733000 | Phase II | CPI-613 + Gemcitabine + Hydroxychloroquine CPI-613 + Hydroxychloroquine CPI-613 + Gemcitabine CPI-613 + Fluorouracil + Hydroxychloroquine | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | Recruiting | USA | 0 |
NCT05736731 | Phase Ib/II | A2B530 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1) | Recruiting | USA | 0 |
NCT05746897 | Phase I | NM1F + Pembrolizumab NM1F | A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05769959 | Phase Ib/II | RO7515629 | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors | Recruiting | USA | 0 |
NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |
NCT05789069 | Phase I | HFB200603 HFB200603 + Tislelizumab | A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05821777 | Phase Ib/II | LB101 | A Study to Evaluate Safety, Tolerability and Preliminary Activity of LB101 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05826600 | Phase I | OMX-0407 | A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically | Recruiting | ESP | 0 |
NCT05843188 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hydroxychloroquine + Irinotecan + Leucovorin | Study of Hydroxychloroquine With FOLFIRI and Bevacizumab in DTP-high Metastatic Colorectal Cancer | Not yet recruiting | CAN | 0 |
NCT05848739 | Phase I | ST316 | A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Not yet recruiting | USA | 0 |